What are the diagnostic workup and treatment options for Myelodysplastic syndrome?

Myelodysplastic Syndrome: Diagnostic Workup and Treatment

All newly diagnosed MDS patients must be evaluated at a center with specific hematologic competence to ensure comprehensive diagnostic assessment, including bone marrow examination with morphology, cytogenetics, and exclusion of non-malignant causes of cytopenias 1.

Diagnostic Workup

Initial Exclusion of Non-Malignant Causes

Before pursuing MDS diagnosis, systematically exclude reversible causes of cytopenias:

• Exposure history: Prior chemotherapy, radiation therapy, radioimmunotherapy, radioiodine, benzene exposure (occupational or hobby-related) 1
• Medications and substances: Current medications, alcohol intake, smoking history 1
• Infection screening: HIV, parvovirus B19 (especially in hypoplastic presentations), cytomegalovirus, hepatitis B/C (particularly in transfusion-dependent patients) 1
• Family history: In younger patients, specifically inquire about inherited bone marrow failure syndromes (Fanconi anemia, telomere disorders) 1
• Physical examination: Document spleen size, bleeding/bruising tendency 1

Mandatory Laboratory Studies

Hematology panel 1:

• Complete blood count with differential
• RBC indices (mean cell volume)
• Reticulocyte count
• Detailed morphology of RBCs, leukocytes, and platelets

Biochemistry panel 1:

• RBC-folate/serum folic acid and cobalamin (exclude nutritional deficiencies)
• Iron studies: serum iron, total iron binding capacity, ferritin
• Lactate dehydrogenase, bilirubin, haptoglobin (assess hemolysis)

Additional testing 1:

• Paroxysmal nocturnal hemoglobinuria clone screening
• Specific genetic analyses if inherited bone marrow failure suspected

Mandatory Bone Marrow Evaluation

The diagnostic triad requires 1:

1. Bone marrow aspirate: Evaluate dysplasia in one or more hematopoietic cell lines, enumerate blasts, count ring sideroblasts, assess cellularity and CD34+ cells
2. Bone marrow biopsy: Assess marrow cellularity, fibrosis, and topography
3. Cytogenetic analysis: Detect acquired clonal chromosomal abnormalities for diagnosis and prognostic assessment

Important caveat: If only unilineage dysplasia is present, no blast increase, ring sideroblasts <15%, and no recurrent cytogenetic abnormalities, observe for 6 months with repeat bone marrow examination before confirming MDS diagnosis 1. These patients typically have mild cytopenia and unlikely rapid progression.

Recommended Additional Studies

• FISH: When standard G-banding repeatedly fails to detect targeted chromosomal abnormalities 1
• Flow cytometry immunophenotyping: Detect abnormalities in erythroid, myeloid, and lymphoid compartments 1

---

Treatment Approach

Treatment is fundamentally divided by risk stratification using IPSS-R (Revised International Prognostic Scoring System), which incorporates cytopenias, bone marrow blast percentage, and cytogenetics 2.

Higher-Risk MDS Treatment

For higher-risk MDS patients without major comorbidities, azacitidine is the standard first-line therapy if not immediately eligible for allogeneic stem cell transplantation (allo-SCT) 2.

Treatment Algorithm for Higher-Risk MDS:

Age <70 years, no major comorbidities, donor available 2:

• Allo-SCT is the priority (only potentially curative option)
• If marrow blasts ≥10%: reduce blast count before allo-SCT using AML-like chemotherapy or hypomethylating agents (HMAs), especially for non-myeloablative conditioning

Age <70 years, fit patients with favorable cytogenetics and marrow blasts ≥10% 2:

• AML-like chemotherapy as bridge to allo-SCT

Not immediately eligible for allo-SCT 2:

• Azacitidine (improves survival in higher-risk MDS)

---

Lower-Risk MDS Treatment

Treatment is symptom-directed based on the predominant cytopenia 2.

For Symptomatic Anemia:

Patients WITHOUT del(5q):

First-line: Erythropoiesis-stimulating agents (ESAs) 2:

• Indication: Baseline EPO <200-500 U/L and absent or limited transfusion requirement
• Dosing: EPO alpha 30,000-80,000 units weekly OR darbepoetin 150-300 mcg weekly
• Expected response: 40-60% erythroid response rate
• Response timing: Within 8-12 weeks
• Duration: Median 20-24 months
• Enhancement: Add G-CSF to improve efficacy
• Note: Only EPO alpha (and biosimilars) formally approved by EMA for lower-risk MDS with serum EPO <200 U/L

Second-line after ESA failure 2:

• MDS with ring sideroblasts (MDS-RS) or SF3B1 mutation: Luspatercept (63% erythroid response, 38% RBC transfusion independence)
• Younger patients with favorable features: Antithymocyte globulin (ATG) ± cyclosporine
• Other options (not approved in Europe): Lenalidomide + ESA, azacitidine (if approved)

Patients WITH del(5q):

First-line: Lenalidomide 2:

• Indication: Transfusion-dependent anemia in lower-risk MDS with del(5q)
• Dosing: 10 mg/day for 3 weeks every 4 weeks
• Expected response: 60-65% RBC transfusion independence
• Duration: Median 2-2.5 years
• Cytogenetic response: 50-75% (including 30-45% complete response)
• Critical monitoring: TP53 mutations (present in ~20%) confer resistance and higher AML progression risk—requires intensified surveillance
• Toxicity: Grade 3-4 neutropenia/thrombocytopenia in ~60% during first weeks; close monitoring with dose reduction and/or G-CSF as needed
• Note: In EU, approved only after ESA failure or ineligibility

Pitfall: ESAs have lower response rates and shorter duration in del(5q) MDS compared to non-del(5q) 2

For Symptomatic Neutropenia:

• Fever: Broad-spectrum antibiotics immediately 2
• Short-term G-CSF for severe neutropenia 2

For Symptomatic Thrombocytopenia:

• Thrombopoietin receptor agonists (TPO-RAs): Romiplostim or eltrombopag have some efficacy but NOT approved for MDS; use only if marrow blasts <5% 2
• Alternative options: ATG (if favorable features), azacitidine (if approved), clinical trial 2

---

Iron Overload Management

Iron chelation is strongly recommended in allo-SCT candidates with transfusion iron overload 2. Even moderate iron overload before transplant increases transplant-related mortality.

For non-transplant candidates with lower-risk MDS 2:

• Strongly recommended: Major iron overload (significantly reduced cardiac T2* by MRI)
• Controversial: Without major iron overload
• Initiation criteria: 20-60 RBC concentrates received OR serum ferritin >1000-2500 U/L

Chelation options 2:

• Deferasirox (oral, preferred)—contraindicated in renal failure
• Deferoxamine (parenteral)
• Deferiprone (oral)—not approved in most countries for MDS due to neutropenia risk

---

Follow-Up Strategy

Regular blood counts to detect worsening cytopenias requiring intervention 2:

• Anemia or severe thrombocytopenia requiring transfusions
• Severe neutropenia mandating infection prevention during invasive procedures
• Rapid antibiotic initiation for infection symptoms

Bone marrow examination 2:

• Triggered by worsening cytopenias or circulating blasts
• NOT routinely scheduled at regular intervals
• Repeat examinations weeks to months apart may be needed to establish diagnosis or identify rapid progression 1